Scarica l'app Stockscreener
32.93
0.92%
0.30
Dopo l'orario di chiusura:
33.29
0.36
+1.09%
Precedente Chiudi:
$32.63
Aprire:
$32.75
Volume 24 ore:
1.50M
Relative Volume:
1.25
Capitalizzazione di mercato:
$3.93B
Reddito:
$10.12M
Utile/perdita netta:
$-280.49M
Rapporto P/E:
-11.39
EPS:
-2.89
Flusso di cassa netto:
$-188.51M
1 W Prestazione:
+10.99%
1M Prestazione:
+13.24%
6M Prestazione:
-27.75%
1 anno Prestazione:
+169.26%
Intervallo 1D:
$32.44
$33.88
Intervallo di 1 settimana:
$29.30
$33.88
Portata 52W:
$11.23
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Nome
Avidity Biosciences Inc
Settore
Industria
Telefono
858-401-7900
Indirizzo
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Confronta RNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
32.93 | 3.93B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-09-24 | Iniziato | Goldman | Buy |
| 2024-08-28 | Iniziato | Barclays | Overweight |
| 2024-05-03 | Iniziato | BofA Securities | Buy |
| 2024-03-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Strong Buy |
| 2021-09-07 | Iniziato | Evercore ISI | Outperform |
| 2021-06-17 | Iniziato | Needham | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | Cowen | Outperform |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | SVB Leerink | Outperform |
| 2020-07-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Avidity Biosciences Inc Borsa (RNA) Ultime notizie
We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely - Yahoo Finance
How to Take Advantage of moves in (RNA) - Stock Traders Daily
Avidity Biosciences (NASDAQ:RNA) Stock Price Up 6%Here's Why - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Avidity Biosciences CEO Sarah Boyce sells $297k in stock - MSN
Avidity Biosciences' chief medical officer sells shares totaling $112,856 - MSN
Assenagon Asset Management S.A. Invests $1.18 Million in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences CHRO Teresa McCarthy sells $84,611 in stock - MSN
Avidity Biosciences chief scientific officer sells shares worth $162,191 - MSN
Avidity Biosciences director sells $53,536 in stock - MSN
Avidity Biosciences, Inc. (NASDAQ:RNA) CFO Michael F. Maclean Sells 3,287 Shares - MarketBeat
Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 2,959 Shares of Stock - MarketBeat
Sarah Boyce Sells 10,397 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock - MarketBeat
Avidity Biosciences CHRO Teresa McCarthy sells $84,611 in stock By Investing.com - Investing.com Canada
Arthur A. Levin Sells 1,872 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock - MarketBeat
Avidity Biosciences director sells $53,536 in stock By Investing.com - Investing.com Canada
Avidity Biosciences CFO sells $93,985 in stock By Investing.com - Investing.com Canada
Avidity Biosciences chief program officer sells shares worth $206,799 By Investing.com - Investing.com Canada
Avidity Biosciences chief program officer sells shares worth $206,799 - Investing.com India
Avidity Biosciences' chief medical officer sells shares totaling $112,856 By Investing.com - Investing.com Australia
Avidity Biosciences CEO Sarah Boyce sells $297k in stock By Investing.com - Investing.com UK
Analysts Offer Predictions for RNA FY2025 Earnings - MarketBeat
Leerink Partnrs Has Negative Estimate for RNA Q1 Earnings - MarketBeat
Royal Bank of Canada Reiterates Outperform Rating for Avidity Biosciences (NASDAQ:RNA) - MarketBeat
Avidity Biosciences Announces Inducement Grants Under Nasdaq Lis - GuruFocus.com
Exciting News from Avidity Biosciences! New Opportunities Await! - Qhubo
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StreetInsider.com
Avidity Biosciences Awards New Employee Stock Options and RSUs Worth $304K - StockTitan
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Avidity Biosciences, Inc. (RNA): The Biotech Stock with Biggest Upside Potential - Insider Monkey
Avidity Set To File First Of Three Muscular Dystrophy Drugs In 2025 - News & Insights
Avidity Biosciences Inc (RNA-Q) QuotePress Release - The Globe and Mail
Avidity Biosciences Becomes Oversold (RNA) - Nasdaq
Avidity Biosciences (NASDAQ:RNA) Sees Large Volume IncreaseHere's Why - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Given Buy Rating at HC Wainwright - MarketBeat
Analyst Expectations For Avidity Biosciences's Future - Benzinga
JPMorgan Chase & Co. Has $21.45 Million Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
Avidity Biosciences, Inc. Announces 2025 Upcoming Clinical and Regulatory Highlights - Marketscreener.com
Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 - PR Newswire
Avidity Biosciences Awards $31.42 Stock Options to New Chief Technical Officer | RNA Stock News - StockTitan
Principal Financial Group Inc. Reduces Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives $64.36 Average Target Price from Analysts - MarketBeat
Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now? - Insider Monkey
Companies Like Avidity Biosciences (NASDAQ:RNA) Are In A Position To Invest In Growth - Simply Wall St
12 Best Multibagger Stocks to Buy Right Now - Insider Monkey
Avidity Biosciences Inc Azioni (RNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):